Document:

EX-10.5

 Exhibit 10.5 

Form of Lock-Up Agreement 

May 2, 2019 
 New Misonix, Inc.

 1938 New Highway 
 Farmingdale, NY 11735 

Re: New Misonix, Inc. Lock-Up Agreement 

Ladies and Gentlemen: 
 The undersigned
understands that New Misonix, Inc., a New York corporation and a direct, wholly owned subsidiary of Misonix, Inc. (“ParentCo”), has entered into an Agreement and Plan of Merger with Solsys Medical, LLC, a Delaware limited liability
company (“Surge”) and the other parties thereto, in the form attached hereto as Exhibit A (the “Merger Agreement”), providing for, among other things, the issuance of ParentCo Common Stock as Surge Closing
Merger Consideration to the undersigned (collectively the “Undersigned’s Lock-Up Securities”), and that such Lock-Up Securities shall be subject to
a Registration Statement on Form S-4 filed with the Securities and Exchange Commission (the “SEC”). Capitalized terms used and not defined in this
Lock-Up Agreement shall have the meaning given to such terms in the Merger Agreement. 
 In
consideration of the agreement by ParentCo to consummate the transactions contemplated by the Merger Agreement, including the issuance of the Lock-Up Securities, and of other good and valuable consideration
the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby agrees that, with respect to the Undersigned’s Lock-Up Securities, during the period beginning from the Closing Date and
continuing to and including the 12 month anniversary of the Closing Date (the “Lock-Up Period”), the undersigned will not, directly or indirectly, (a) pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any of the Undersigned’s Lock-Up Securities, (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any of the Undersigned’s Lock-Up Securities, whether any such transaction is to be settled by delivery of such Lock-Up Shares, in cash or otherwise or (c) publicly disclose the intention to make
any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any of the Undersigned’s Lock-Up Securities. The foregoing restrictions are expressly
agreed to preclude the undersigned from engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of the Undersigned’s
Lock-Up Securities even if such Lock-Up Securities would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would
include any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to any of the Undersigned’s Lock-Up Securities or with respect to any
security that includes, relates to, or derives any significant part of its value from such Undersigned’s Lock-Up Securities. 

  
 1 

 Notwithstanding the foregoing, the undersigned may transfer or otherwise dispose of the
Undersigned’s Lock-Up Securities: 
  

	 	(i)	 a sale of up to thirty percent (30%) of the shares of ParentCo Common Stock received by the undersigned solely
in connection with the settlement of EARs pursuant to Section 1.7(f) of the Merger Agreement; 

  

	 	(ii)	 to any trust solely for the direct or indirect benefit of the undersigned or the immediate family of the
undersigned, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value; 

 

	 	(iii)	 to any immediate family member, any investment fund, family partnership, family limited liability company or
other entity controlled or managed by the undersigned; 

  

	 	(iv)	 by will or intestacy, provided that the legatee, heir or other transferee, as the case may be, agrees to be
bound in writing by the restrictions set forth herein; 

  

	 	(v)	 pursuant to a court order or settlement agreement related to the distribution of assets in connection with the
dissolution of a marriage or civil union; provided that the recipient agrees to be bound in writing by the restrictions set forth herein; 

  

	 	(vi)	 to ParentCo pursuant to agreements under which ParentCo, or one of its Subsidiaries, has the option to
repurchase such Lock-Up Securities or in connection with a cancellation of such Lock-Up Securities by ParentCo pursuant to agreements of the undersigned governing the
payment of Surge Closing Merger Consideration; 

  

	 	(vii)	 as part of a distribution, transfer or disposition without consideration by the undersigned to its limited or
general partners, members, stockholders or affiliates (as defined under Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), provided that each transferee
agrees to be bound in writing by the restrictions set forth herein; 

  

	 	(viii)	 pursuant to a bona fide third-party merger, consolidation, tender offer or other similar transaction involving
a Change of Control of ParentCo that is approved by ParentCo’s board of directors and made to all holders of ParentCo Common Stock, provided that, in the event that such Change of Control is not completed, the Undersigned’s Lock-Up Securities shall remain subject to the restrictions contained in this Lock-Up Agreement and title to the Undersigned’s
Lock-Up Securities shall remain with the undersigned; 

  

	 	(ix)	 to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under
foregoing clauses (i) through (viii); or 

  

	 	(x)	 with the prior written consent of ParentCo (to be granted or withheld in ParentCo’s sole and absolute
discretion). 

	 	

	 	

  
 2 

 For purposes of this Lock-Up Agreement,
“immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin. In addition, notwithstanding the foregoing, if the undersigned is a corporation, partnership, limited liability
company, trust or other business entity, the undersigned may transfer the Undersigned’s Lock-Up Securities by transfer to any corporation, partnership, limited liability company or other legal entity
that, directly or indirectly, controls, is controlled by, or is under common control with, the undersigned; provided, however, that in any such case, it shall be a condition to the transfer that the transferee execute an agreement
stating that the transferee is receiving and holding such capital stock subject to the provisions of this agreement and there shall be no further transfer of such capital stock except in accordance with this agreement, and provided further that any
such transfer shall not involve a disposition for value. Notwithstanding anything to the contrary, in the case of clauses (i) through (vi) above, no filing under the Exchange Act or any other public filing or disclosure of such transfer by or
on behalf of the undersigned shall be required or voluntarily made during the Lock-up Period (other than a filing on a Form 5 and other than a required filing on Schedule 13G, Schedule 13G/A or Form 13F). For
the purposes of clause (ix) above, “Change of Control” shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person
or group of affiliated persons, of ParentCo’s voting securities if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities of ParentCo (or the surviving entity), and in each
case excluding the issuance of shares of ParentCo Common Stock pursuant to the terms of the Merger Agreement. 
 Notwithstanding the foregoing, the
undersigned may establish a trading plan pursuant to Rule 10b5-1 under the Exchange Act, provided, that (i) no public report or filing under Section 16 of the Exchange Act shall be required during
the Lock-Up Period, (ii) the undersigned does not otherwise voluntarily effect any public filing or report regarding the establishment of such plan during the
Lock-Up Period and (iii) no sales are made during the Lock-Up Period pursuant to such plan. 

The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this agreement. 

The undersigned also agrees and consents to the entry of stop transfer instructions with ParentCo’s transfer agent and registrar against
the transfer of the Undersigned’s Lock-Up Securities except in compliance with the foregoing restrictions. 

This agreement and any claim, controversy or dispute arising under or related to this agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof and the undersigned hereby irrevocably submits to the exclusive jurisdiction in the U.S. District Court for the District of Delaware for any
action or proceeding arising out of or relating to this agreement or the transactions contemplated hereby. 
 [Signature Page Follows] 

  
 3 

 The undersigned understands that ParentCo is relying upon this Lock-Up Agreement in proceeding toward consummation of the transactions contemplated by the Merger Agreement, including the issuance of the Undersigned’s Lock-Up
Securities. The undersigned further understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors, and assigns. This Lock-Up Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or
other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

This Lock-Up Agreement (and for the avoidance of doubt, the
Lock-Up Period described herein) and related restrictions shall automatically terminate upon the termination of the Merger Agreement pursuant to Section 6.1 thereof. 

 

			
	Very truly yours,
	
	 
	 Name of Security Holder (Print exact name)

		
	By:	 	 
		 	Signature
	
	If not signing in an individual capacity:
	
	 
	 Name of Authorized Signatory (Print)

	
	 
	 Title of Authorized Signatory (Print)

	
	(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity))

 [Signature Page to Lock-Up Agreement]Exhibit 4.2

 

PURCHASE
WARRANT

 

Issued
to:

 

 

 

Exercisable
to Purchase

 

_________Shares
of Common Stock

  

of

 

NEUROONE
MEDICAL

TECHNOLOGIES

CORPORATION

 

Warrant
No. P -  ______  

 

Void
after July 1, 2024

 

THE
SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT (1) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AND THE SECURITIES LAWS
OF OTHER JURISDICTIONS AND, IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION
OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH
OTHER APPLICABLE LAWS.

 

     

     

    

 

This
is to certify that, for value received and subject to the terms and conditions set forth below, the Warrantholder (hereinafter
defined) is entitled to purchase, and the Company (hereinafter defined) promises and agrees to sell and issue to the Warrantholder,
at any time on or after the Issue Date and on or before the fifth anniversary of the Issue Date, up to [_] shares of Common Stock
(hereinafter defined) at the per share Exercise Price (hereinafter defined).

 

This
Warrant Certificate is issued subject to the following terms and conditions:

 

1.
Definitions of Certain Terms. Except as may be otherwise clearly required by the context, the following terms have the
following meanings:

 

(a)
“Cashless Exercise” means an exercise of a Warrant in which, in lieu of payment of the Exercise Price in cash, the Warrantholder
elects to receive a lesser number of Securities in payment of the Exercise Price, as determined in accordance with Section 2(b).

 

(b)
“Closing Date” means the date or dates on which a closing under the Offering occurs.

 

(c)
“Commission” means the Securities and Exchange Commission.

 

(d)
“Common Stock” means the common stock, $0.001 par value, of the Company.

 

(e)
“Company” means NeuroOne Medical Technologies Corporation, a Delaware corporation.

 

(f)
“Exercise Price” means the price at which the Warrantholder may purchase one share of Common Stock or other Securities
upon exercise of a Warrant as determined from time to time pursuant to the provisions hereof, multiplied by the number of Securities
as to which the Warrant is being exercised. The initial Exercise Price is $2.75 per share of Common Stock.

 

(g)
“Issue Date” means the Closing Date on which this Warrant is issued.

 

(h)
“Memorandum” means the offering materials described in the Placement Agent Agreement.

 

(i)  
“Offering” means the private offering of shares of Common Stock and warrants made pursuant to the Memorandum and the
Placement Agent Agreement.

 

(j)  
“Placement Agent Agreement” means that certain Placement Agent Agreement, dated December 12, 2018 between the Company,
Paulson Investment Company, LLC and any Additional Placement Agents as defined therein, as amended.

 

(k)
“Rules and Regulations” means the rules and regulations of the Commission adopted under the Securities Act.

 

(l)  
“Securities” means the securities obtained or obtainable upon exercise of the Warrant or securities obtained or obtainable
upon exercise, exchange, or conversion of such securities.

 

    2

     

    

 

(m)
“Securities Act” means the Securities Act of 1933, as amended.

 

(n)
“Warrant” means the warrant evidenced by this certificate, any similar certificate issued in connection with the Offering,
or any certificate obtained upon transfer or partial exercise of the Warrant evidenced by any such certificate.

 

(o)
“Warrant Certificate” means a certificate evidencing the Warrant.

 

(p)
“Warrantholder” means a record holder of the Warrant or Securities.

 

2.
Exercise of Warrant.

 

(a)
All or any part of the Warrant represented by this Warrant Certificate may be exercised commencing on the Issue Date and ending
at 5:00 p.m. Pacific Time on (the “Expiration Date”) by surrendering this Warrant Certificate, together with the Exercise
Price and appropriate instructions, duly executed by the Warrantholder or by its duly authorized attorney, at the office of the
Company, 10006 Liatris Lane Eden Prairie, MN 55347; or at such other office or agency as the Company may designate. The date on
which such instructions are received by the Company shall be the date of exercise. If the Warrantholder has elected a Cashless
Exercise, such instructions shall so state.

 

(b)
If the Warrantholder elects a Cashless Exercise, the Warrantholder may surrender in payment of the Exercise Price, shares of Common
Stock equal in value to the Exercise Price by surrender of this Warrant at the principal office of the Company together with notice
of such election, in which event the Company shall issue to the Warrantholder a number of shares of Common Stock computed using
the following formula:

 

X =          Y
( A - B)

A

		

 

	Where:	X
=	The number of shares of Common Stock to
                 be issued to the Warrantholder pursuant to this Cashless Exercise
	 	 	 
		Y
                              =	The
                                         number of shares of Common Stock in respect of which the Cashless Exercise election is
                                         made

 

		A
                              =	The
                                         fair market value of one share of Common Stock at the time the Cashless Exercise election
                                         is made

 

		B =
	The
Exercise Price (as adjusted to the date of the Cashless Exercise)

 

For
purposes of this Section 2(b), the fair market value of one share of Common Stock as of a particular date shall be determined
as follows: (i) if traded on a securities exchange, the value shall be deemed to be the closing price of the Common Stock on such
exchange one (1) trading day prior to the Cashless Exercise; (ii) if traded over-the-counter, the value shall be deemed to be
the closing bid or sale price (whichever is applicable) of the Common Stock one (1) trading day prior to the Cashless Exercise;
and (iii) if there is no active public market, the value shall be the fair market value thereof, as determined in good faith by
the Board of Directors of the Company.

 

    3

     

    

 

(c)
Subject to the provisions below, upon receipt of notice of exercise, the Company shall promptly prepare or cause the preparation
of certificates for the Securities to be received by the Warrantholder upon completion of the Warrant exercise. After such certificates
are prepared, the Company shall notify the Warrantholder and, upon payment in full by the Warrantholder, in lawful money of the
United States, of the Exercise Price payable with respect to the Securities being purchased, or, in the case of a Cashless Exercise,
upon deemed surrender of Securities equal in value to the Exercise Price, deliver such certificates to the Warrantholder, or as
per the Warrantholder’s instructions, promptly after such funds are available, if applicable, and otherwise promptly thereafter.
The Securities to be obtained on exercise of the Warrant will be deemed to have been issued, and any person exercising the Warrant
will be deemed to have become a holder of record of those Securities, as of the date of receipt by the Company of (a) available
funds in cash in payment of the Exercise Price, or (b) notice of Cashless Exercise.

 

(d)
If fewer than all the Securities purchasable under the Warrant are purchased, the Company will, upon such partial exercise, execute
and deliver to the Warrantholder a new Warrant Certificate (dated the date hereof), in form and tenor similar to this Warrant
Certificate, evidencing that portion of the Warrant not exercised.

 

(e)
Notwithstanding the foregoing, in no event shall such Securities be issued, and the Company is authorized to refuse to honor the
exercise of the Warrant, if such exercise would result in the opinion of the Company’s Board of Directors, upon advice of counsel,
in the violation of any law.

 

3.
Adjustments in Certain Events. The number, class, and price of Securities for which this Warrant Certificate may be exercised
are subject to adjustment from time to time upon the happening of certain events as follows:

 

(a)
If the outstanding shares of the Company’s Common Stock are divided into a greater number of shares or a dividend in stock is
paid on the Common Stock, the number of shares of Common Stock for which the Warrant is then exercisable will be proportionately
increased and the Exercise Price will be proportionately reduced; and, conversely, if the outstanding shares of Common Stock are
combined into a smaller number of shares of Common Stock, the number of shares of Common Stock for which the Warrant is then exercisable
will be proportionately reduced and the Exercise Price will be proportionately increased. The increases and reductions provided
for in this Section 3(a) will be made with the intent and, as nearly as practicable, the effect that neither the percentage of
the total equity of the Company obtainable on exercise of the Warrants nor the price payable for such percentage upon such exercise
will be affected by any event described in this Section 3(a).

 

(b)
In case of any change in the Common Stock through merger, consolidation, reclassification, reorganization, partial or complete
liquidation, purchase of substantially all the assets of the Company, or other change in the capital structure of the Company,
then, as a condition of such change, lawful and adequate provision will be made so that the Warrantholder will have the right
thereafter to receive upon the exercise of the Warrant the kind and amount of shares of stock or other securities or property
to which the Warrantholder would have been entitled if, immediately prior to such event, the Warrantholder had held the number
of shares of Common Stock obtainable upon the exercise of the Warrant. In any such case, appropriate adjustment will be made in
the application of the provisions set forth herein with respect to the rights and interest thereafter of the Warrantholder, to
the end that the provisions set forth herein will thereafter be applicable, as nearly as reasonably may be, in relation to any
shares of stock or other securities or property thereafter deliverable upon the exercise of the Warrant. The Company will not
permit any change in its capital structure to occur unless the issuer of the shares of stock or other securities to be received
by the holder of this Warrant Certificate, if not the Company, agrees to be bound by and comply with the provisions of this Warrant
Certificate.

 

    4

     

    

 

(c)
When any adjustment is required to be made in the number of shares of Common Stock, other securities, or the property purchasable
upon exercise of the Warrant, the Company will promptly determine the new number of such shares or other securities or property
purchasable upon exercise of the Warrant and (i) prepare and retain on file a statement describing in reasonable detail the method
used in arriving at the new number of such shares or other securities or property purchasable upon exercise of the Warrant and
(ii) cause a copy of such statement to be mailed to the Warrantholder within thirty (30) days after the date of the event giving
rise to the adjustment.

 

(d)
No fractional shares of Common Stock or other Securities will be issued in connection with the exercise of the Warrant, and the
number of shares of Common Stock to be issued shall be rounded to the nearest whole number.

 

(e)
If securities of the Company or securities of any subsidiary of the Company are distributed pro rata to holders of Common Stock,
such number of securities will be distributed to the Warrantholder or its assignee upon exercise of its rights hereunder as such
Warrantholder or assignee would have been entitled to if this Warrant had been exercised prior to the record date for such distribution.
The provisions with respect to adjustment of the Common Stock provided in this Section 3 will also apply to the securities to
which the Warrantholder or its assignee is entitled under this Section 3(e).

 

(f)
Notwithstanding anything herein to the contrary, there will be no adjustment made hereunder on account of the sale by the Company
of the Common Stock or any other Securities purchasable upon exercise of the Warrant.

 

4.
Reservation of Securities. The Company agrees that the number of shares of Common Stock or other Securities sufficient
to provide for the exercise of the Warrant upon the basis set forth above will, at all times during the term of the Warrant, be
reserved for issuance.

 

5.
Validity of Securities. All Securities delivered upon the exercise of the Warrant will be duly and validly issued in accordance
with their terms and, upon payment of the Exercise Price, will be fully paid and non-assessable. The Company will pay all documentary
and transfer taxes, if any, in respect of the original issuance thereof upon exercise of the Warrant.

 

6.
Transferability. This Warrant Certificate and the Warrant may be transferred to Additional Placement Agents in the Offering
as defined in the Placement Agent Agreement or to individuals who are a partner, officer or other representative of the Lead Placement
Agent or any Additional Placement Agent. The Warrant may be divided or combined, upon request to the Company by the Warrantholder,
into a certificate or certificates evidencing the same aggregate number of Warrants.

 

    5

     

    

 

7.
Securities Act Compliance. The Warrantholder hereby represents: (a) that this Warrant and any Common Stock to be acquired
by the Warrantholder on exercise of the Warrant will be acquired for investment for the Warrantholder’s own account and not with
a view to the resale or distribution of any part thereof, and (b) that the Warrantholder is an accredited investor as defined
in Rule 501(a) of Regulation D promulgated under the Securities Act. In addition, as a condition of its delivery of certificates
for the Common Stock, the Company will require the Warrantholder to deliver to the Company representations regarding the Warrantholder’s
sophistication, investor status, investment intent, acquisition for its own account and such other matters as are reasonable and
customary for purchasers of securities in an unregistered private offering as set forth in the attached Exercise Form. The Company
may place conspicuously upon each certificate representing the Common Stock a legend substantially in the following form, the
terms of which are agreed to by the Warrantholder:

 

“THE
SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT (1) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AND THE SECURITIES LAWS
OF OTHER JURISDICTIONS AND, IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION
OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH
OTHER APPLICABLE LAWS.”

 

8.
No Rights as a Shareholder. Except as otherwise provided herein, the Warrantholder will not, by virtue of ownership of
the Warrant, be entitled to any rights of a shareholder of the Company but will, upon written request to the Company, be entitled
to receive such quarterly or annual reports as the Company distributes to its shareholders.

 

    6

     

    

 

9.
Notice. Any notices required or permitted to be given hereunder will be in writing and may be served personally or by mail,
including by e-mail; and if served will be addressed as follows:

 

	 	If to the Company:	NeuroOne Medical Technologies Corporation
	 	 	Attn: Dave Rosa 
	 	 	10901 Red Circle Drive, Suite 150, 

Minnetonka, MN 55343
	 		Email: daver@neurooneinc.com
	 	 	 
	 	with a copy to:	Honigman LLP 
	 	 	Attn: Phillip Torrence
	 	 	650 Trade Centre Way, Suite 200
	 	 	Portage, Michigan 49002
	 		Email: ptorrence@honigman.com
	 	 	 
	 	If to the Warrantholder:	                                                                 

 

Any
notice so given by mail will be deemed effectively given 48 hours after mailing when deposited in the United States mail, registered
or certified mail, return receipt requested, postage prepaid and addressed as specified above. Any notice given by e-mail must
be accompanied by confirmation of receipt, and will be deemed effectively given upon confirmation of such receipt. Any party may
by written notice to the other specify a different address for notice purposes.

 

10.
Applicable Law. This Warrant Certificate will be governed by and construed in accordance with the laws of the State of
Washington, without reference to conflict of laws principles thereunder. All disputes relating to this Warrant Certificate shall
be tried before the courts of Washington located in Clark County, Washington to the exclusion of all other courts that might have
jurisdiction.

 

[The
remainder of this page intentionally left blank]

 

    7

     

    

 

In
Witness Whereof, the Company has caused this
Warrant to be signed by its duly authorized officer.

 

	Dated as of July 1, 2019	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
	 	 
	 	By:	              
	 	Name: 	Dave Rosa
	 	Title: 	Chief Executive Officer

 

Signature
Page to Purchase Warrant

 

    8

     

    

 

EXERCISE
FORM

(To
Be Executed by the Warrantholder to Exercise the Warrant)

 

		TO:	NEUROONE
MEDICAL TECHNOLOGIES CORPORATION

 

		1.	The
                                         undersigned hereby irrevocably elects to exercise the right to purchase                                        

shares
of Common Stock, represented by Warrant No. P –                               as follows:

 

		☐	Exercise for
                                                                                                                                                                        Cash. Pursuant to Section 2(a) of the Warrant, the Holder hereby elects to exercise the Warrant for cash and tenders
                                                                                                                                                                        payment herewith (or has made a wire transfer) to the order of NeuroOne Medical Technologies Corporation in the amount of 
	 	 	$
                          . 

 

	2.	☐	Cashless Exercise. Pursuant to Section 2(b)
of the Warrant, the Holder hereby elects to exercise the Warrant on a cashless basis.

 

		3.	The
undersigned requests that the applicable number of shares of Common Stock be issued and delivered to the following address:

 

	 	Name:	                       	 
	 	Address:	 	 
	 	 	 	 
	 	 
	 	Email:	 	 
	 	SSN:	 	 

 

		4.	The
undersigned understands, agrees and recognizes that:

 

		(a)	No
federal or state agency has made any finding or determination as to the fairness of the investment or any recommendation or endorsement
of the securities.

 

		(b)	All
                                         certificates evidencing the shares of Common Stock, if any, may bear a legend substantially
                                         similar to the legend set forth in Section 7 of the Warrant regarding resale restrictions.

 

Representations
of the undersigned.

 

		5.	The
undersigned acknowledges that the undersigned has received, read and understood the Warrant and agrees to abide by and be bound
by its terms and conditions.

 

		6.	(i) 	The undersigned has such knowledge and experience in
business and financial matters that the undersigned is capable of evaluating the Company and the proposed activities thereof,
and the risks and merits of this prospective investment.

 

☐  
YES  ☐ NO

 

    9

     

    

 

		(ii)	If
“No”, the undersigned is represented by a “purchaser representative,” as that term is defined in Regulation
D under the Securities Act of 1933, as amended (the “Securities Act”).

 

☐  
YES  ☐ NO

 

		7.	(i) 	The undersigned is an “accredited investor,”
as that term is defined in the Securities Act.

 

☐  
YES  ☐ NO

 

		(ii)	If
“Yes,” the undersigned comes within the following category of that definition (check one):

 

		☐	The
undersigned is a natural person whose present net worth (or whose joint net worth with his or her spouse), excluding the value
of the undersigned’s primary residence, exceeds $1,000,000. For purposes of calculating the undersigned’s present
net worth, the undersigned has included the following as liabilities: (i) any indebtedness that is secured by the undersigned’s
primary residence in excess of the estimated fair market value of the undersigned’s primary residence at the time of the
sale of the shares, and (ii) any incremental debt secured by the undersigned’s primary residence that was incurred in the
60 days before the sale of the shares, other than as a result of the acquisition of the undersigned’s primary residence.

 

		☐	The
undersigned is a natural person who had individual income in excess of $200,000 in each of the last two years or joint income
with the undersigned’s spouse in excess of $300,000 during such two years, and the undersigned reasonably expects to
have the same income level in the current year.

 

		☐	The
undersigned is an officer or director of the Company.

 

		☐	The
undersigned is a corporation or partnership not formed for the specific purpose of acquiring the securities offered, with total
assets in excess of $5,000,000.

 

		☐	The
undersigned is a trust with total assets in excess of $5,000,000 whose purchase is directed by a person with such knowledge and
experience in financial and business matters that such person is capable of evaluating the merits and risks of the prospective
investment.

 

		☐	The
undersigned is an entity, all of whose equity owners are accredited investors under one or more of the categories above.

 

		8.	The
undersigned understands that the shares purchased hereunder have not been registered under the Securities Act, in reliance upon
the exemption from the registration requirements under the Securities Act pursuant to Section 4(2) of the Securities Act and Rule
506 promulgated thereunder; and, therefore, that the undersigned must bear the economic risk of
the investment for an indefinite period of time since the securities cannot be sold, transferred or assigned to any person or
entity without compliance with the provisions of the Securities Act.

 

    10

     

    

 

	Dated:                            
    , 2019	 	 
	 	By:	 
		Name:	 
	 	Print:	 
	 	 	 
	 	 Note: Signature must correspond with the name as written upon the face of the Warrant in all respects, without alteration or enlargement or any change whatsoever.

 

 

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]